These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8021707)

  • 21. Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system.
    Miklyaeva EI; Dong W; Bureau A; Fattahie R; Xu Y; Su M; Fick GH; Huang JQ; Igdoura S; Hanai N; Gravel RA
    Brain Res; 2004 Mar; 1001(1-2):37-50. PubMed ID: 14972652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosing Lysosomal Storage Disorders: The GM2 Gangliosidoses.
    Hall P; Minnich S; Teigen C; Raymond K
    Curr Protoc Hum Genet; 2014 Oct; 83():17.16.1-8. PubMed ID: 25271840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene Therapy of Sphingolipid Metabolic Disorders.
    Shaimardanova AA; Solovyeva VV; Issa SS; Rizvanov AA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nomenclature of GM2-gangliosidoses.
    Nørby S
    Clin Genet; 1980 May; 17(5):320-2. PubMed ID: 7192191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of microtechniques for the detection of lysosomal enzyme disorders: Tay-Sachs disease, Gm1-gangliosidosis and Fabry disease.
    Bladon MT; Milunsky A
    Clin Genet; 1978 Dec; 14(6):359-66. PubMed ID: 215359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
    Kolter T; Sandhoff K
    J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
    Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
    Tsuji D; Higashine Y; Matsuoka K; Sakuraba H; Itoh K
    Clin Chim Acta; 2007 Mar; 378(1-2):38-41. PubMed ID: 17196574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presence of beta-hexosaminidase A alpha-chain mRNA in two different variants of GM2-gangliosidosis.
    Budde-Steffen C; Steffen M; Siegel DA; Suzuki K
    Neuropediatrics; 1988 May; 19(2):59-61. PubMed ID: 2967444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomedical genetics of the inherited metabolic diseases: the GM2-gangliosidoses.
    Kolodny EH
    Am J Ment Defic; 1984 Mar; 88(5):582-9. PubMed ID: 6428229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the hexosaminidase genes: mouse models of the GM2 gangliosidoses.
    Proia RL
    Adv Genet; 2001; 44():225-31. PubMed ID: 11596985
    [No Abstract]   [Full Text] [Related]  

  • 32. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
    Sango K; McDonald MP; Crawley JN; Mack ML; Tifft CJ; Skop E; Starr CM; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1996 Nov; 14(3):348-52. PubMed ID: 8896570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of enzyme and DNA analysis in a Tay-Sachs disease carrier screening program.
    Yoo HW; Astrin KH; Desnick RJ
    J Korean Med Sci; 1993 Feb; 8(1):84-91. PubMed ID: 8343225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An inducible mouse model of late onset Tay-Sachs disease.
    Jeyakumar M; Smith D; Eliott-Smith E; Cortina-Borja M; Reinkensmeier G; Butters TD; Lemm T; Sandhoff K; Perry VH; Dwek RA; Platt FM
    Neurobiol Dis; 2002 Aug; 10(3):201-10. PubMed ID: 12270683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
    Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
    Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diagnostic journey for patients with late-onset GM2 Gangliosidoses.
    Lopshire MC; Tifft C; Burns J; Gould R; Zheng R; Batsu I
    Mol Genet Metab Rep; 2023 Dec; 37():101014. PubMed ID: 38053937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid detection of fetal Mendelian disorders: Tay-Sachs disease.
    Guetta E; Peleg L
    Methods Mol Biol; 2008; 444():147-59. PubMed ID: 18425478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses.
    Cavender C; Mangini L; Van Vleet JL; Corado C; McCullagh E; Gray-Edwards HL; Martin DR; Crawford BE; Lawrence R
    PLoS One; 2020; 15(12):e0243006. PubMed ID: 33259552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
    Kobayashi T; Goto I; Okada S; Orii T; Ohno K; Nakano T
    J Neurochem; 1992 Oct; 59(4):1452-8. PubMed ID: 1402895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis.
    Tsuji D; Akeboshi H; Matsuoka K; Yasuoka H; Miyasaki E; Kasahara Y; Kawashima I; Chiba Y; Jigami Y; Taki T; Sakuraba H; Itoh K
    Ann Neurol; 2011 Apr; 69(4):691-701. PubMed ID: 21520232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.